Cargando…

Profile of Nivolumab in the Treatment of Resected Esophageal Squamous Cell Carcinoma: A Review of the Clinical Data

Esophageal cancer (EC) is the seventh most common malignancy globally. There are two main histological subtypes: esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma. ESCC is the predominant histological type of esophageal cancer worldwide and has worse prognosis than esophageal a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Yuntae, Yamamoto, Shun, Kato, Ken
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10183349/ https://www.ncbi.nlm.nih.gov/pubmed/37197006 http://dx.doi.org/10.2147/CMAR.S390499

Ejemplares similares

Nivolumab induced hyperprogressive disease in advanced esophageal squamous cell carcinoma
por: Sun, Dantong, et al.
Publicado: (2020)

Effectiveness of taxanes following nivolumab in patients with advanced esophageal squamous cell carcinoma: a retrospective chart review of patients in ATTRACTION-3
por: Chin, Keisho, et al.
Publicado: (2022)

Five-year follow-up of nivolumab treatment in Japanese patients with esophageal squamous-cell carcinoma (ATTRACTION-1/ONO-4538-07)
por: Satoh, Taroh, et al.
Publicado: (2021)

Safety and short-term efficacy of preoperative FOLFOX therapy in patients with resectable esophageal squamous cell carcinoma who are ineligible for cisplatin
por: Kadono, Toru, et al.
Publicado: (2022)

Ability of Blood Cell Parameters to Predict Clinical Outcomes of Nivolumab Monotherapy in Advanced Esophageal Squamous Cell Carcinoma
por: Hamai, Yoichi, et al.
Publicado: (2023)

Cost-effectiveness analysis of nivolumab combination therapy in the first-line treatment for advanced esophageal squamous-cell carcinoma
por: Liu, Shixian, et al.
Publicado: (2022)

Defining conversion therapy for esophageal squamous cell carcinoma
por: Matsuda, Satoru, et al.
Publicado: (2022)

Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck
por: Hanna, Glenn J., et al.
Publicado: (2022)

Three-Year Follow-Up and Response–Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3)
por: Okada, Morihito, et al.
Publicado: (2022)

Tadalafil Enhances Immune Signatures in Response to Neoadjuvant Nivolumab in Resectable Head and Neck Squamous Cell Carcinoma
por: Luginbuhl, Adam J., et al.
Publicado: (2022)

Endoscopic resection of esophageal squamous cell carcinoma: Current indications and treatment outcomes
por: Abe, Seiichiro, et al.
Publicado: (2021)

Nivolumab for Metastatic Cutaneous Squamous Cell Carcinoma
por: Oro-Ayude, Marcos, et al.
Publicado: (2020)

Immune checkpoint inhibitors in esophageal cancer: Clinical development and perspectives
por: Nagata, Yusuke, et al.
Publicado: (2022)

Clinical Remission of Cutaneous Squamous Cell Carcinoma of the Auricle with Cetuximab and Nivolumab
por: Chen, Alessandra, et al.
Publicado: (2018)

Profile of nivolumab in the treatment of metastatic squamous non-small-cell lung cancer
por: Ang, Yvonne LE, et al.
Publicado: (2016)

Current perspectives of the Japanese Esophageal Oncology Group on the development of immunotherapy for esophageal cancer
por: Kadono, Toru, et al.
Publicado: (2022)

Primary squamous cell carcinoma of the pleura treated with nivolumab
por: Sigala, Ioanna, et al.
Publicado: (2020)

Optimal Adjuvant Treatment for Curatively Resected Thoracic Esophageal Squamous Cell Carcinoma: A Radiotherapy Perspective
por: Kim, Kyung Hwan, et al.
Publicado: (2017)

Pembrolizumab for first-line treatment of advanced unresectable or metastatic esophageal or gastroesophageal junction cancer
por: Hirose, Toshiharu, et al.
Publicado: (2023)

Real-world clinical outcomes of nivolumab and taxane as a second- or later-line therapy for recurrent or unresectable advanced esophageal squamous cell carcinoma
por: Ohsawa, Manato, et al.
Publicado: (2023)

Nivolumab Combined With Ipilimumab Treatment Induced Hypophysitis and Immune-Mediated Liver Injury in Advanced Esophageal Squamous Cell Carcinoma: A Case Report
por: Feng, Yi, et al.
Publicado: (2022)

What Is the Next Step after Endoscopic Resection of Superficial Esophageal Squamous Cell Carcinoma?
por: Kim, Sang Gyun
Publicado: (2015)

Neoadjuvant versus adjuvant treatment: which one is better for resectable esophageal squamous cell carcinoma?
por: Xu, Yaping, et al.
Publicado: (2012)

Salvage treatment for lymph node recurrence after radical resection of esophageal squamous cell carcinoma
por: Chen, Jie, et al.
Publicado: (2019)

Neoadjuvant chemoradiotherapy plus surgery in the treatment of potentially resectable thoracic esophageal squamous cell carcinoma
por: Yan, Mao-Hui, et al.
Publicado: (2020)

Mediastinal Neuroendocrine Carcinoma Slowly Growing for 8 Years after Surgical Resection of Esophageal Squamous Cell Carcinoma
por: Hirose, Suguru, et al.
Publicado: (2020)

Efficacy and Safety of Endoscopic Resection Followed by Chemoradiotherapy for Superficial Esophageal Squamous Cell Carcinoma: A Retrospective Study
por: Hamada, Kenta, et al.
Publicado: (2017)

Prophylactic steroid administration for strictures after endoscopic resection of large superficial esophageal squamous cell carcinoma
por: Kadota, Tomohiro, et al.
Publicado: (2016)

Efficacy of intensity-modulated radiotherapy for resected thoracic esophageal squamous cell carcinoma
por: Zhang, Wencheng, et al.
Publicado: (2015)

Preoperative Diagnosis and Indications for Endoscopic Resection of Superficial Esophageal Squamous Cell Carcinoma
por: Matsueda, Katsunori, et al.
Publicado: (2020)

Tertiary lymphoid structures favor outcome in resected esophageal squamous cell carcinoma
por: Li, Rutao, et al.
Publicado: (2022)

Neoadjuvant immunotherapy for resectable esophagal squamous cell carcinoma: An ace up the sleeve
por: Zhou, Qing, et al.
Publicado: (2023)

Conditional Survival of Patients Who Underwent Curative Resection for Esophageal Squamous Cell Carcinoma
por: Shin, Dong Wook, et al.
Publicado: (2022)

Surgically Resected Esophageal Squamous Cell Carcinoma: Patient Survival and Clinicopathological Prognostic Factors
por: Jeong, Dong Young, et al.
Publicado: (2020)

Colonic Perforation After Treatment With Nivolumab in Esophageal Cancer: A Case Report
por: Cho, Hye Jung, et al.
Publicado: (2021)

Development and Validation of an Esophageal Squamous Cell Carcinoma Detection Model by Large-Scale MicroRNA Profiling
por: Sudo, Kazuki, et al.
Publicado: (2019)

The clinical significance of preoperative plasma fibrinogen level and platelet count in resectable esophageal squamous cell carcinoma
por: Wang, Jianbo, et al.
Publicado: (2015)

Clinical Significance of Preoperative Thrombin Time in Patients with Esophageal Squamous Cell Carcinoma following Surgical Resection
por: Li, Xiao-Hui, et al.
Publicado: (2015)

Failure patterns after adjuvant chemoradiotherapy following endoscopic resection for superficial esophageal squamous cell carcinoma
por: Ikawa, Toshiki, et al.
Publicado: (2019)

Neoadjuvant chemoradiotherapy followed by esophagectomy vs. surgery alone in the treatment of resectable esophageal squamous cell carcinoma
por: FUJIWARA, YOSHINORI, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_6qknid7mlpbhsrcrsrmhi50p5j